Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Cannabinoid Technologies Holdings Plc LSE:OCTP London Ordinary Share GB00BMVMRB86 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.025 -3.13% 0.775 2,346,273 08:00:00
Bid Price Offer Price High Price Low Price Open Price
0.75 0.80 0.775 0.775 0.775
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -5.50 -0.49 7
Last Trade Time Trade Type Trade Size Trade Price Currency
16:37:56 O 500,000 0.79 GBX

Oxford Cannabinoid Techn... (OCTP) Latest News

More Oxford Cannabinoid Techn... News
Oxford Cannabinoid Techn... Investors    Oxford Cannabinoid Techn... Takeover Rumours

Oxford Cannabinoid Techn... (OCTP) Discussions and Chat

Oxford Cannabinoid Techn... Forums and Chat

Date Time Title Posts
25/1/202312:26Oxford cannabinoid with charts215
05/1/202315:37Oxford cannabinoid technologies 358

Add a New Thread

Oxford Cannabinoid Techn... (OCTP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Cannabinoid Techn... trades in real-time

Oxford Cannabinoid Techn... (OCTP) Top Chat Posts

Top Posts
Posted at 28/1/2023 08:20 by Oxford Cannabinoid Techn... Daily Update
Oxford Cannabinoid Technologies Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OCTP. The last closing price for Oxford Cannabinoid Techn... was 0.80p.
Oxford Cannabinoid Technologies Holdings Plc has a 4 week average price of 0.75p and a 12 week average price of 0.48p.
The 1 year high share price is 2.56p while the 1 year low share price is currently 0.48p.
There are currently 960,415,644 shares in issue and the average daily traded volume is 7,808,291 shares. The market capitalisation of Oxford Cannabinoid Technologies Holdings Plc is £7,443,221.24.
Posted at 12/1/2023 07:05 by zxie
OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.
Posted at 05/1/2023 15:44 by sep800
OCTP have come along way since the IPO 18 months ago, And the markets at that time 5p was a sensible value. Since then OCTP have incurred the usual drop in the share price due to lack of activity as most companies sort their admin out in the first 12 months together with the markets shorting the share price as a safe calculated risk due to the given factors.
However £0.005p was well over done and the Markets have now u-turned as OCTP gain advantages from its trials with a product well known to the medical industry.
We are now going to see the share price raise to a more suitable level especially given the commencement of the trials, With £5M cash which means no fund raising this year.
We have so much news to follow very soon and with OCTP on track to deliver a product this year, I see no reason why the share price short term to be 2.5p-3p moving up on further positive news.
Certainly plenty of up side from here and one to hold onto at least prior to results.
Any positive news will accelerate the share price northwards and with just A small amount of free float shares available, the share price will rise quickly just as we have seen in the last week.
I believe the MM's got caught out last week and are trying to force sellers to balance their books, however if there are no sellers to share price will keep rising.
Either way I believe we are in a good position ready for any positive news to land.
GLA

Posted at 05/1/2023 15:37 by sep800
OCTP have come along way since the IPO 18 months ago, And the markets at that time 5p was a sensible value. Since then OCTP have incurred the usual do rop in the share price due to lack of activity as most companies sort their admin out in the first 12 months together with the markets shorting the share price as a safe calculated risk due to the given factors.
However £0.005p was well over done and the Markets are now u-turned as OCTP gain advantages from its trials with a product well known to the medical industry.
We are now going to see the share price raise to a more suitable level especially given the commencement of the trials together with £5M cash which means no fund raising this year.
We have so much news to follow very soon and with OCTP on track to deliver a product this year, I see no reason way the share price short term be 2.5p-3p moving up on further positive news.
Certainly plenty of up side from here and one to hold onto at least prior to results.
Any positive news will accelerate the share price northwards and with small amount of free float shares available, the share price will rise quickly just as we have seen in the last week.
I believe the MM's got caught out last week and are trying to force sellers to balance their books, however if there are no sellers to share price will keep rising.
Either way I believe your in a good position ready for any positive news to land.
GL

Posted at 04/1/2023 14:31 by pillow
Slowly but surely share price recovers awsome potential here would not suprise me if this rapidly moves back to IPO level. Watching with great interest now ahead of imminent news.
Posted at 04/1/2023 11:28 by hooded claw
sep8003 Jan '23 - 02:01 - 191 of 194
0 9 0

With so much positive news due as per interview, OCTP will be one to hold for 2023.
IPO 5p, now just 0.08p ..... what a bargain

------------------------

Do you mean 0.8p ? Started with the right unit on IPO then decided to convert to pounds. I would keep it simple if I were you

Posted at 03/1/2023 02:01 by sep800
When funding is hampering many other companies. OCTP are in excellent shape and fully funded till end 2023.
With so much positive news due as per interview, OCTP will be one to hold for 2023.
IPO 5p, now just 0.08p ..... what a bargain

Posted at 02/1/2023 14:15 by tell sid
idiveajag,I would say its almost a foregone conclusion that lead compound OCT461201 will pass Phase 1. Cannabinoids are well known and widely used, but this one is more precisely targeted, so should be even safer and better tolerated.The current OCTP MCap is only £7m (less than the price of a London apartment). That leaves plenty of headway to make OCTP shares a 10x bagger by trial start, and a 20x bagger on positive trial results.
Posted at 30/12/2022 10:29 by idriveajag
OCTP should be above 4p on start of the trial next month.
Posted at 12/12/2022 07:57 by manual dexterity
Oxford Cannabinoid Tech.Holdings Trading Update
12/12/2022 7:00am
UK Regulatory (RNS & others)

Oxford Cannabinoid Techn... (LSE:OCTP)
Intraday Stock Chart

Monday 12 December 2022

Click Here for more Oxford Cannabinoid Techn... Charts.
TIDMOCTP

RNS Number : 2871J

Oxford Cannabinoid Tech.Holdings

12 December 2022

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Trading Update

Continued progress, commencement of clinical trials of lead drug candidate imminent

Financial and operational targets remain on track and on budget

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market, announces a positive trading and operational update for the six months ended 31 October 2022 ("the Period").

Financial Highlights

The budget review, announced on 26 August 2022, realigned the Company's development and expenditure programme to focus on bringing the Company's lead compound, OCT461201, through Phase I clinical trials. Taking this action meant that funds, which would otherwise have been fully utilised by April 2023, are now expected to extend to Q4 2023.

Importantly, the Company remains on track and on budget to commence clinical trials for OCT461201 in January 2023, with publication of its interim results for the period ended 31 October 2022 also anticipated in January 2023.

During the Period, the Group incurred c.GBP3.1 million of R&D costs, with progress being made on all four programmes. As at 31 October 2022, OCTP and its subsidiary, Oxford Cannabinoid Technologies Ltd. ("OCT"), (together, "the Group") had total cash reserves of approximately GBP5 million and remained debt free.

Operational update

Operational progress has been consistent with the Board's expectations and the Board remains confident that OCTP will achieve the milestones set out in its current development timeline.

Work under the Group's GBP2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE (together "Evotec"), which commenced in July 2021 is now almost complete. Evotec will provide the Company with a submission-ready regulatory document by the end of December 2022 and will deliver an approved batch of drug product to the OCT461201 Programme 1 Phase I clinical trial unit during Q1 2023.

In addition to the progress made on OCT461201, pre-clinical work for OCT130401 is almost complete, ensuring that Programme 2 will be Phase I ready in early 2023 at which time further development will be placed on hold in order to preserve cash. Development work for Programmes 3 and 4 has also continued, with the Company still on target to be at pre-clinical stage (for programme 3) and lead stage (for programme 4) with these programmes by Q2 2023.

Clarissa Sowemimo-Coker, Interim CEO of OCTP, said: " We are incredibly pleased with the ongoing progress and the fact that we remain on track to meet our financial and operational targets. This is a big achievement and is testament to the adaptability, skill, and "can do" attitude of Dr Valentino Parravicini, his team, and our external partners.

"As OCTP nears a critical juncture in its journey to introduce prescription cannabinoid medicines to the US$ multi-billion pain market, we are carefully managing cash and are well placed to deliver on our key objectives. I look forward to updating the market on our continued progress with the half-year results."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this announcem

Posted at 28/11/2022 09:27 by sep800
OCTP Been on my Radar for a while now. Price as level at 0.05p, Having dropped from 5p IPO. Been buying lately at such a give away price. This was 3.5p last year, Plenty of cash to see them through June 2023 so no need to raise. With trials starting soon and with media attention due to be released, expecting an uplift to the current share price
Great entry at this level.

Oxford Cannabinoid Techn... share price data is direct from the London Stock Exchange
Your Recent History
LSE
OCTP
Oxford Can..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230129 02:35:43